RMTG Cellgenic expands into Colombia
Analysis based on 6 articles · First reported Sep 08, 2026 · Last updated Sep 08, 2026
The announcement is a minor positive for RMTG as it expands its international footprint, but it does not change the company's fundamental financial risks. Given RMTG's going-concern uncertainty and lack of revenue guidance, market impact is expected to be negligible.
Regenerative Medical Technology Group, Inc. (RMTG), through its Cellgenic division, announced on September 8, 2026, that it has commenced local commercial arrangements in Colombia, including establishing local representation and developing relationships with physicians and medical providers in permitted channels. This follows similar arrangements in Peru and Brazil, making Colombia the third Latin American market for Cellgenic. The company emphasized that these activities are subject to Colombian regulatory, import, and professional-licensing requirements, and do not constitute product registration or revenue forecasts. RMTG operates through its wholly owned subsidiary Cell Stem Cell and faces ongoing going-concern uncertainty, limited liquidity, and substantial indebtedness.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard